Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-07-11
2006-07-11
Achutamurthy, Ponnathapula (Department: 1652)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S252300, C435S320100
Reexamination Certificate
active
07074911
ABSTRACT:
The instant invention relates to the determination that constitutively nearly silent GrB locus in human breast carcinoma and osteosarcoma cells activated upon retinoblastoma protein (pRB)-induced growth arrest owing to the usage of an alternative promoter/transcription start site. Cloned novel cDNA from the locus adds 34 amino acid residues to the N-terminus of GrB zymogen. The alternate product has been designated as GrB-NIC. Tumor cells with accumulated endogenous GrB-NIC, whose mature form was identical to lymphocyte GrB but with a distinctive glycosylation pattern, undergoes post-growth-arrest apoptosis that occurs concurrently with pRB cleavage, and are capable of inducing rapid apoptosis of bystander pRB−tumor cells. Expression of GrB-NIC is also observed in malignant cells of other types as well as in normal non-immune cells upon cell differentiation, especially in differentiating and differentiated neural cells. GrB-NIC plays a physiological role in embryonic, and particularly in early neuronal development. The disclosure further provides compositions and methods utilizing this new GrB-NIC technology.
REFERENCES:
patent: 5858758 (1999-01-01), Hillman et al.
patent: 5965711 (1999-10-01), Hillman et al.
patent: 6537784 (2003-03-01), Tatake et al.
patent: 6607879 (2003-08-01), Cocks et al.
patent: 6812339 (2004-11-01), Venter et al.
patent: 2003/0086919 (2003-05-01), Rosenblum et al.
patent: 2003/0143530 (2003-07-01), Klepp et al.
patent: WO 1991/10685 (1991-07-01), None
patent: WO 99/43840 (1999-09-01), None
patent: WO 2002/34910 (2002-05-01), None
patent: WO 2002/46467 (2002-06-01), None
patent: WO 2002/68579 (2002-09-01), None
patent: WO 2003/016475 (2003-02-01), None
Caputo, A., et al., 1990, “Nucleotide sequence and genomic organization of a human T lymphocyte serine protease gene”, Journal of Immunology, vol. 145, No. 2, pp. 737-744.
Dahl et al., 1990, “Isolation of a cDNA encoding a novel form of granzyme B from human NK cells”, Human Genetics, vol. 84, pp. 465-470.
Haddad, P., et al., 1990, “Structural organization of the hCTLA-1 gene encoding a human granzyme B”, Gene, vol. 87, No. 2, pp. 265-271.
Hanson et al., 1990, “Transcriptional activation of the human cytotoxic serine protease gene CSP-B in T lymphocytes”, Molecular and Cellular Biology, vol. 10, No. 11, pp. 5655-5662.
Caputo et al., 1988, “Structure and differential mechanisms of regulation of expression of a serine gene in activated human T lymphocytes”, The Journal of Biological Chemistry, vol. 263, No. 13, pp. 6363-6369.
Trapani, J.A., et al., 1988, “Molecular cloning of an inducible serine esterase gene from human cytotoxic lymphocytes”, Proceedings of the National Academy of Sciences, U.S.A., vol. 85, No. 18, pp. 6924-6928.
An, B., and Dou, Q. P. (1996). Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate. Cancer Res. 56, 438-442.
Babichuk, C.K., Duggan, B.L., and Bleackley, R.C. (1996). In vivo regulation of murine granzyme B gene transcription in activated primary T cells. J. Biol. Chem. 271, 16485-16493.
Berthou, C., et al. (1995). Granzyme B and perforin lytic proteins are expressed in CD34+peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor. Blood 86, 3500-3506.
Berthou, C., et al. (1997). Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J. Immunol. 159, 5293-5300.
Bruno, A.P., et al. (2000). Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin. Blood 96, 1914-1920.
Chen, P.L., et al. (1992). Stability of retinoblastoma gene expression determines the tumorigenicity of reconstituted retinoblastoma cells. Cell Growth Differ. 3, 119-125.
Chen, W.D., et al. (1997). Apoptosis is associated with cleavage of a 5-kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene 14, 1243-1248.
Cordon-Cardo, C., and Richon, V.M. (1994). Expression of the retinoblastoma protein is regulated in normal human tissues. Am. J. Pathol. 144, 500-510.
Dyson, N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev. 12: 2245-2262.
Fattman, C.L., et al. (1998). p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Letters 130,103-113.
Graubert, T.A., et al. (1997). Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100, 904-911.
Haas-Kogan, D.A., et al. (1995). Inhibition of apoptosis by the retinoblastoma gene product. EMBO J. 14, 461-472.
Heusel, J.W., et al. (1994). Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76, 977-987.
Hirst, C.E., et al. Perforin-independent expression of granzyme B and proteinase inhibitor 9 in human testis and placenta suggests a role for granzyme B-mediated proteolysis in reproduction. Molecular Human Reproduction, 7:1133-1142, 2001.
Hofmann, F., et al. (1996). The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 10, 2949-2959.
Hu, SX, et al. (2003) Expression of endogenous granzyme B in a subset of human primary breast carcinomas. Br. J. Can. 89(1):135-9.
Huang, H.J., et al. (1988). Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242, 1563-1566.
Kennea, NL, and Mehmet, H.J (2002) Neural stem cells, Pathol., 197(4):536-50.
Klein, J.L., et al. (1989). Genomic organization and chromosomal assignment for a serine protease gene (CSPB) expressed by human cytotoxic lymphocytes. Genomics 5, 110-117.
Kontani, K., et al. (2001). Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers. Eur. J. Surg. Oncol. 27, 180-186.
Krek, W., et al. (1995). Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell, 83: 1149-1158.
Lobe, C.G., et al. (1986). Novel serine proteases encoded by two cytotoxic T lymphocyte-specific genes. Science 232, 858-861.
Motyka, B., et al. (2000) Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103, 491-500.
Ogura, Y., et al. (2001). Apoptosis and allograft rejection in the absence of CD830T cells. Transplantation 71, 1827-1834.
Pinkoski, M. J., et al. (2000). Nuclear translocation of granzyme B in target cell apoptosis. Cell Death Differ. 7, 17-24.
Qin, X.Q., et al. (1992). Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6, 953-964.
Romano, G., et al. (2000) Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications Stem Cells 18: 19-39.
Schmid, J., and Weissmann, C. (1987) Induction of mRNA for a serine protease and a β-thrombo-globulin-like protein in mitogen-stimulated human leukocytes. J. Immunol. 139, 250-256.
Shan, B., et al. (1996). The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Cell Growth Differ. 7, 689-697.
Shi, L., et al. (1997). Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J. Exp. Med. 185, 855-866.
Shresta, S., et al. (1997). Mechanisms responsible for granzyme B-independent cytotoxicity. Blood 89, 4085-4091.
Sun, J., et al. (2001). Importance of the P4′ residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop. J. Biol. Chem. 276, 15177-15184.
Tan, X., et al. (1997). Degradation of retinoblastoma protein in tumor necrosis factor and CD95-induced cell death. J. Biol. Chem. 272
Hu Shi-Xue
Mills Gordon B.
Xu Hong-Ji
Achutamurthy Ponnathapula
Moore William W.
Vinson & Elkins LLP
LandOfFree
Endogenous granzyme B in non-immune cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endogenous granzyme B in non-immune cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endogenous granzyme B in non-immune cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3540648